@article {Lo3114, author = {Shih-Wei Lo and Ming-Hsin Li and Shih-Min Wang and Ming-Wei Chen and wei-lin lo}, title = {Evaluation of MH-PC-AB-53 peptideas a carcinoma therapeutic agent}, volume = {61}, number = {supplement 1}, pages = {3114--3114}, year = {2020}, publisher = {Society of Nuclear Medicine}, abstract = {3114Objectives: MH-PC-AB-53 showed high binding affinity for prostate-specific membrane antigen. Radiolabeled PSMA peptides that are prostate specific can be used for prostate -targeted radiotheragnostic application. The MH-PC-AB-53 (15-30μg) was labeled with ~3 or ~6mCi InCl3 (from INER) in sodium acetate (NaOAc) with different pH values (4.0-6.0) at 95{\textcelsius} within 15mins. After labeling with In-111, quality control was performed by RP-HPLC and radio thin layer chromatography. Radiochemical purity was analyzed in the radio-TLC scanner with a 0.1M citric acid solution as the mobile phase. The Rf of free In-111 was approximately 0.95, and the Rf of 111In -MH-PC-AB-53 was approximately 0.05. The Radiochemical purity of the 111In-MH-PC-AB-53 was assayed by TLC(96.8\%) and HPLC (96\%). LNCaP tumor bearing mice were intravenously injected with 111In -MH-PC-AB-53. Scans were performed 1, 4, and 24 h after the administration. 111In-MH-PC-AB-53 showed high tumor uptake at all time points.}, issn = {0161-5505}, URL = {https://jnm.snmjournals.org/content/61/supplement_1/3114}, eprint = {https://jnm.snmjournals.org/content}, journal = {Journal of Nuclear Medicine} }